CA2278152A1 - Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate - Google Patents
Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate Download PDFInfo
- Publication number
- CA2278152A1 CA2278152A1 CA002278152A CA2278152A CA2278152A1 CA 2278152 A1 CA2278152 A1 CA 2278152A1 CA 002278152 A CA002278152 A CA 002278152A CA 2278152 A CA2278152 A CA 2278152A CA 2278152 A1 CA2278152 A1 CA 2278152A1
- Authority
- CA
- Canada
- Prior art keywords
- methotrexate
- disease
- autoimmune
- bystander
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
US60/036,722 | 1997-01-24 | ||
PCT/US1998/001648 WO1998032451A1 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2278152A1 true CA2278152A1 (fr) | 1998-07-30 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002278152A Abandoned CA2278152A1 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (fr) |
JP (1) | JP2001511134A (fr) |
KR (1) | KR20000070460A (fr) |
AU (1) | AU6648898A (fr) |
BR (1) | BR9807112A (fr) |
CA (1) | CA2278152A1 (fr) |
HU (1) | HUP0001960A2 (fr) |
IL (1) | IL131025A0 (fr) |
NO (1) | NO993600L (fr) |
WO (1) | WO1998032451A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068290A2 (fr) | 2002-02-11 | 2003-08-21 | Antares Pharma, Inc. | Injecteur intradermique |
BRPI0614025A2 (pt) | 2005-01-24 | 2012-12-25 | Antares Pharma Inc | injetores de jato |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
WO2009114542A1 (fr) | 2008-03-10 | 2009-09-17 | Antares Pharma, Inc. | Dispositif de sécurité pour injecteur |
ES2738539T3 (es) | 2008-08-05 | 2020-01-23 | Antares Pharma Inc | Inyector de dosis múltiples |
AU2010226442A1 (en) | 2009-03-20 | 2011-10-13 | Antares Pharma, Inc. | Hazardous agent injection system |
CA2802853C (fr) | 2010-06-16 | 2016-07-26 | Bruce Chandler May | Utilisation de la levocetirizine et du montelukast dans le traitement de la grippe, du rhume et d'une inflammation |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
KR20150003179A (ko) | 2012-03-06 | 2015-01-08 | 안타레스 팔마, 인코퍼레이티드 | 분리력 특징을 가진 사전충전형 주사기 |
EP4186545A1 (fr) | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Administration par injection par jet assistée par aiguille de compositions de testostérone |
WO2013169800A1 (fr) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Dispositif d'injection ayant un ensemble piston à came |
ES2763633T3 (es) | 2013-02-11 | 2020-05-29 | Antares Pharma Inc | Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida |
JP6030803B2 (ja) | 2013-03-11 | 2016-11-24 | アンタレス・ファーマ・インコーポレーテッド | ピニオンシステムを有する用量注射器 |
WO2014165136A1 (fr) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Seringues pré-remplies à volume constant et leurs trousses |
MX2015011905A (es) | 2013-03-13 | 2016-01-08 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. |
WO2014164282A1 (fr) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique |
WO2014164299A1 (fr) * | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1336954C (fr) * | 1987-06-24 | 1995-09-12 | Howard L. Weiner | Traitement des maladies auto-immunes par l'administration d'auto-antigenes par voie orale |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
JPH05507501A (ja) * | 1990-09-06 | 1993-10-28 | リックスウーニーベルシテイト・テ・ウットレヒト | リンパ球応答と免疫関連疾患との阻害剤 |
EP0627933B1 (fr) * | 1992-02-28 | 2002-11-27 | Autoimmune, Inc. | Suppression de maladies auto-immunes par des antigenes en attente |
WO1996040235A1 (fr) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t |
US6010722A (en) * | 1995-06-13 | 2000-01-04 | Nippon Meat Packers, Inc. | Oral remedy for rheumatoid arthritis and functional food |
-
1998
- 1998-01-26 CA CA002278152A patent/CA2278152A1/fr not_active Abandoned
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/pt not_active Application Discontinuation
- 1998-01-26 IL IL13102598A patent/IL131025A0/xx unknown
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/fr not_active Application Discontinuation
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/ko not_active Application Discontinuation
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/hu unknown
- 1998-01-26 EP EP98908452A patent/EP0994717A4/fr not_active Withdrawn
- 1998-01-26 JP JP53225298A patent/JP2001511134A/ja active Pending
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU6648898A (en) | 1998-08-18 |
HUP0001960A2 (hu) | 2000-10-28 |
EP0994717A4 (fr) | 2000-07-26 |
WO1998032451A1 (fr) | 1998-07-30 |
EP0994717A1 (fr) | 2000-04-26 |
NO993600L (no) | 1999-09-23 |
BR9807112A (pt) | 2001-09-18 |
KR20000070460A (ko) | 2000-11-25 |
JP2001511134A (ja) | 2001-08-07 |
NO993600D0 (no) | 1999-07-23 |
IL131025A0 (en) | 2001-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2278152A1 (fr) | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate | |
US5935577A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
AU720695B2 (en) | Bystander suppression of autoimmune diseases | |
WO1998032451A9 (fr) | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate | |
US6645504B1 (en) | Bystander suppression of type I diabetes by oral administration of glucagon | |
EP0506785A1 (fr) | Traitement ameliore de maladies auto-immunes par administration par aerosol d'auto-antigenes | |
Krause et al. | Immunomodulation of experimental autoimmune diseases via oral tolerance | |
AU695883B2 (en) | Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines | |
AU686797B2 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
US20010007758A1 (en) | Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines | |
WO2001089557A2 (fr) | Methodes de prevention des accidents vasculaires cerebraux moyennant l'induction d'une tolerance a e-selectin | |
Virella et al. | Organ-specific autoimmune diseases | |
US20040115217A1 (en) | Bystander suppression of autoimmune diseases | |
JP2001502306A (ja) | インシュリン依存性糖尿病の処置方法および組成物 | |
Benson | Efficacy and mechanisms of oral tolerance to myelin basic protein in relapsing experimental autoimmune encephalomyelitis | |
Daniel | Analysis of insulin-specific T cells in the pathogenesis of autoimmune diabetes | |
JP2003512435A (ja) | 予防及び治療方法 | |
HAFLER et al. | I. OVERVIEW OF HUMAN AUTOIMMUNE DISEASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |